Business Context and Reporting Period
This Form 8-K filing by CHF Solutions, Inc. (trading symbol: CHFS) is dated September 3, 2019. The report addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on board composition and director compensation terms.
Material Changes
- Board Expansion: The Board size was set at seven (7) members effective September 3, 2019.
- New Appointment: Dr. Maria Rosa Costanzo was appointed to fill a vacancy and serve as a Class I director.
- Committee Assignment: Dr. Costanzo was appointed to the Nominating and Corporate Governance Committee.
Management Commentary and Compensation Details
Dr. Costanzo brings significant medical expertise, serving as a medical director at Advocate Heart Institute and Edward Hospital Center, with over 250 peer-reviewed publications. Her compensation aligns with the company's non-employee director policy:
- Base Retainer: $45,000 annually.
- Committee Fee: $2,000 annually for committee service.
- Equity Award: An automatic grant to purchase up to 1,313 shares of common stock, calculated as a pro rata portion of the annual award based on the time elapsed since the preceding annual meeting.
An Indemnity Agreement was also executed with Dr. Costanzo on September 3, 2019.
Investor Verification Checklist
- Verify the total number of board seats and current vacancies following this appointment.
- Review the definitive proxy statement (Schedule 14A filed April 9, 2019) for the full terms of the director compensation program.
- Confirm the pro rata calculation for the equity award granted to Dr. Costanzo.
- Check for any subsequent filings regarding Dr. Costanzo's re-election status at the 2020 annual meeting.